Menendez indictment could see pharma lose a key ally

Sen.BobMenendez(D-N.J.)MichaelM.Santiago/GettyImagesWASHINGTON—WithmountingcallsforembattledSen.BobM EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3




leisure time

author：knowledge    Page View：34489
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： There’s no way to know how good AI health technologies are
Next article： Wildfire smoke exposes gaps in outdoor worker protections